Multimodality therapy for resectable cancer of the thoracic esophagus.
Publication/Presentation Date
3-1-2002
Abstract
The frequency of esophageal carcinoma continues to increase in North America primarily because of the increased incidence of Barrett's epithelium in the distal esophagus and its malignant potential. Aggressive treatments involving multimodality therapies have been offered to improve overall poor survival rates. A review of this experience follows, to explain the rationale and to compare results of therapies. Although preoperative chemoradiation therapy is commonly used for locally advanced disease, few data support its superiority over surgical resection alone, followed by adjuvant therapy when appropriate. Hence this regimen should be limited to patients enrolled in controlled, randomized studies until the data support its widespread use.
Volume
73
Issue
3
First Page
1009
Last Page
1015
ISSN
0003-4975
Published In/Presented At
Entwistle, J. W., 3rd, & Goldberg, M. (2002). Multimodality therapy for resectable cancer of the thoracic esophagus. The Annals of thoracic surgery, 73(3), 1009–1015. https://doi.org/10.1016/s0003-4975(01)03148-4
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
11899954
Department(s)
Administration and Leadership
Document Type
Article